These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 33429410)

  • 1. Sublingual apomorphine (Kynmobi) for Parkinson's disease.
    Med Lett Drugs Ther; 2020 Oct; 62(1609):165-166. PubMed ID: 33429410
    [No Abstract]   [Full Text] [Related]  

  • 2. Opicapone (Ongentys) - a COMT inhibitor for Parkinson's disease.
    Med Lett Drugs Ther; 2021 Jan; 63(1615):3-5. PubMed ID: 33646998
    [No Abstract]   [Full Text] [Related]  

  • 3. Istradefylline (Nourianz) for Parkinson's disease.
    Med Lett Drugs Ther; 2020 Feb; 62(1591):20-23. PubMed ID: 32022788
    [No Abstract]   [Full Text] [Related]  

  • 4. Comparison chart: Drugs for Parkinson's disease.
    Med Lett Drugs Ther; 2020 Dec; 62(1613):e1-e9. PubMed ID: 33647002
    [No Abstract]   [Full Text] [Related]  

  • 5. Drugs for Parkinson's disease.
    Med Lett Drugs Ther; 2021 Feb; 63(1618):25-32. PubMed ID: 33647001
    [No Abstract]   [Full Text] [Related]  

  • 6. Inhaled levodopa (Inbrija) for Parkinson's disease.
    Med Lett Drugs Ther; 2019 May; 61(1572):73-74. PubMed ID: 31169799
    [No Abstract]   [Full Text] [Related]  

  • 7. Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 study.
    Olanow CW; Factor SA; Espay AJ; Hauser RA; Shill HA; Isaacson S; Pahwa R; Leinonen M; Bhargava P; Sciarappa K; Navia B; Blum D;
    Lancet Neurol; 2020 Feb; 19(2):135-144. PubMed ID: 31818699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease.
    Deleu D; Hanssens Y; Northway MG
    Drugs Aging; 2004; 21(11):687-709. PubMed ID: 15323576
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Continuous subcutaneous infusion of apomorphine for the treatment of Parkinson's disease].
    Drapier S; Vérin M
    Rev Neurol (Paris); 2006 Oct; 162(10):1019-23. PubMed ID: 17028572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel sublingual apomorphine treatment for patients with fluctuating Parkinson's disease.
    Ondo W; Hunter C; Almaguer M; Jankovic J
    Mov Disord; 1999 Jul; 14(4):664-8. PubMed ID: 10435505
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The concept of continuous dopaminergic stimulation in the treatment of late stages of Parkinson's disease].
    Titova NV; Katunina EA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(12):105-12. PubMed ID: 24596973
    [No Abstract]   [Full Text] [Related]  

  • 12. A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease.
    Chen JJ; Obering C
    Clin Ther; 2005 Nov; 27(11):1710-24. PubMed ID: 16368444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apomorphine for the acute treatment of "off" episodes in Parkinson's disease.
    Stacy M; Silver D
    Parkinsonism Relat Disord; 2008; 14(2):85-92. PubMed ID: 18083605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Candidate patient for subcutaneous apomorphine injection].
    Chacón JR; Mata M
    Rev Neurol; 2012; 55 Suppl 1():S7-9. PubMed ID: 23169232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Future delivery systems for apomorphine in patients with Parkinson's disease.
    van Laar T; Van der Geest R; Danhof M
    Adv Neurol; 1999; 80():535-44. PubMed ID: 10410768
    [No Abstract]   [Full Text] [Related]  

  • 16. [Treatment of Parkinson disease in patients with surgical problems].
    Sobolewski P
    Neurol Neurochir Pol; 2003; 37 Suppl 5():183-8. PubMed ID: 15098345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of entacapone and apomorphine coadministration in levodopa-treated Parkinson's disease patients: pharmacokinetic and pharmacodynamic results of a multicenter, double-blind, placebo-controlled, cross-over study.
    Zijlmans JC; Debilly B; Rascol O; Lees AJ; Durif F
    Mov Disord; 2004 Sep; 19(9):1006-1011. PubMed ID: 15372589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sublingual apomorphine in the treatment of Parkinson's disease.
    Kassubek J; Jost WH; Schwarz J
    J Neural Transm (Vienna); 2024 Oct; 131(10):1209-1216. PubMed ID: 38743091
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sublingual apomorphine (APL-130277) for the acute conversion of OFF to ON in Parkinson's disease.
    Hauser RA; Olanow CW; Dzyngel B; Bilbault T; Shill H; Isaacson S; Dubow J; Agro A
    Mov Disord; 2016 Sep; 31(9):1366-72. PubMed ID: 27430123
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apomorphine-subcutaneous--Bertek/Britannia.
    Drugs R D; 2004; 5(4):211-2. PubMed ID: 15230626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.